Onkure Therapeutics Inc
NASDAQ: OKURBoulder, US · Founded 2014 · Delaware corporation · 42 employees on LinkedIn · 7 known investors
Find your way into Onkure Therapeutics Inc
19 people in our graph share verified history with the Onkure Therapeutics Inc team — schools, employers, funds. One of them is your warm intro.
Larry Burgessunlockedknows Dylan Hartley · together at Arraybiopharma (overlapped)
×3knows the team · via Arraybiopharma
×4knows the team · via University of Colorado Anschutz
×4knows the team · via University of Kansas Medical Center
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
Founders & leadership
JL
Jason LeveroneinExecutive
SA
Samuel AgrestainChief Medical Officer
DH
Dylan HartleyinChief Scientific OfficerDylan Hartley is an Executive Officer at OnKure Therapeutics, a clinical-stage biopharmaceutical company developing PI3Kα inhibitors for oncology. He has research experience in drug discovery, metabolism, and toxicology, with postdoctoral studies in toxicology at the University of Kansas Medical Center.
WJ
Wendy JohnsonExecutive
NA
Nicholas A. SaccomanoPresident and Chief Executive Officer and Director
Board
IM
ET
NO
VM
Valerie M. JansenBoard director
RM
R. Michael CarruthersBoard director
MG
Michael G. GreyBoard director
AJ
Andrew Johm PhillipsBoard director
Investors · 7
Access BiotechnologyNew York City
Boulder VenturesBoulder · $1M – $4M
RiverVest Venture PartnersSt. Louis · $500K – $3M
Abingworthreported · 2 sourcesLondon · $15M – $30Mvia Bali Muralidhar · board
ACORN BIOVENTURESreportedNew Yorkvia Isaac Manke · board
New Enterprise Associates (NEA)reported · 2 sourcesMenlo Park · $200K – $40M
Novo HoldingsreportedCopenhagen · $1.1M – $54M
Reported raises · per SEC filings
Form D private placements$159.4M disclosed across 4 rounds · 2017–2024
▶$65MraisedOct 2024 · 20 investors · PharmaceuticalsRule 506(b)
▶$65MraisedOct 2024 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Isaac MankeDirector
- Jason LeveroneExecutive Officer
- Samuel AgrestaExecutive Officer
- Dylan HartleyExecutive Officer
- Edward T. MathersDirector
- Nicholas SaccomanoExecutive Officer, Director
- Valerie M. JansenDirector
- R. Michael CarruthersDirector
- Michael G. GreyDirector
- Andrew Johm PhillipsDirector
- Offering amount
- $65M
- Amount sold
- $65M
- Sales commissions
- $3.3M
- Placement agents
- LifeSci Capital, LLC, Leerlink Partners LLC, Evercore Group, L.L.C
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$47.4MraisedDec 2020 · 15 investors · PharmaceuticalsRule 506(b)
▶$47.4MraisedDec 2020 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gregory FlesherExecutive Officer, Director
- Lon Cardon, Ph.D.Director
- Michael GreyDirector
- Johan Kordel, Ph.D.Director
- Ed MathersDirector
- Niall O'Donnell, Ph.D.Director
- Wendy JohnsonExecutive Officer
- Alejandro Dorenbaum, M.D.Executive Officer
- Kenneth HarrisonDirector
- Bali MuralidharDirector
- Stacey SeltzerDirector
- Mike CruseExecutive Officer
- Offering amount
- $94.8M
- Amount sold
- $47.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedMay 2019 · 9 investors · PharmaceuticalsRule 506(b)
▶$25MraisedMay 2019 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael GreyDirector
- Niall O'Donnell, Ph.D.Executive Officer, Director
- Lon Cardon, Ph.D.Director
- Ed MathersDirector
- Johan Kordel, Ph.D.Director
- Art PappasDirector
- Wendy JohnsonExecutive Officer
- Alejandro Dorenbaum, M.D.Executive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$22MraisedJan 2018 · 16 investors · PharmaceuticalsRule 506(b)
▶$22MraisedJan 2018 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott WeinerDirector
- Wendy JohnsonExecutive Officer
- Michael GreyExecutive Officer, Director
- Niall O'DonnellExecutive Officer, Director
- Ed MathersDirector
- Offering amount
- $52M
- Amount sold
- $22M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$364.6Mvaluation at IPOApr 2021 · $15.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 3
by search overlap
Kura Oncology43 shared keywordsKura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
NovoCure42 shared keywordsNovocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer. The company focuses on patient-centered innovation in oncology.
Bioworld37 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Onkure Therapeutics Inc for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Onkure Therapeutics Inc do?
- OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
- Who are Onkure Therapeutics Inc's investors?
- Onkure Therapeutics Inc's investors include Access Biotechnology, Boulder Ventures, RiverVest Venture Partners, Abingworth, ACORN BIOVENTURES, New Enterprise Associates (NEA), Novo Holdings.
- How much funding has Onkure Therapeutics Inc raised?
- Onkure Therapeutics Inc has disclosed $159.4M raised across 4 rounds.
- Where is Onkure Therapeutics Inc headquartered?
- Onkure Therapeutics Inc is headquartered in Boulder, US.